RTI International, 3040 Cornwallis Road, Durham, NC, 27709, USA.
Aga Khan University, Karachi, Pakistan.
Reprod Health. 2018 Jun 22;15(Suppl 1):89. doi: 10.1186/s12978-018-0528-1.
In South Asia, where most stillbirths and neonatal deaths occur, much remains unknown about the causes of these deaths. About one-third of neonatal deaths are attributed to prematurity, yet the specific conditions which cause these deaths are often unclear as is the etiology of stillbirths. In low-resource settings, most women are not routinely tested for infections and autopsy is rare.
This prospective, cohort study will be conducted in hospitals in Davengere, India and Karachi, Pakistan. All women who deliver either a stillbirth or a preterm birth at one of the hospitals will be eligible for enrollment. With consent, the participant and, when applicable, her offspring, will be followed to 28-days post-delivery. A series of research tests will be conducted to determine infection and presence of other conditions which may contribute to the death. In addition, all routine clinical investigations will be documented. For both stillbirths and preterm neonates who die ≤ 28 days, with consent, a standard autopsy as well as minimally invasive tissue sampling will be conducted. Finally, an expert panel will review all available data for stillbirths and neonatal deaths to determine the primary and contributing causes of death using pre-specified guidance.
This will be among the first studies to prospectively obtain detailed information on causes of stillbirth and preterm neonatal death in low-resource settings in Asia. Determining the primary causes of death will be important to inform strategies most likely to reduce the high mortality rates in South Asia.
Clinicaltrials.gov ( NCT03438110 ) Clinical Trial Registry of India ( CTRI/2018/03/012281 ).
在南亚,大多数死产和新生儿死亡发生在那里,对于这些死亡的原因仍知之甚少。大约三分之一的新生儿死亡归因于早产,但导致这些死亡的具体情况往往不清楚,死产的病因也是如此。在资源匮乏的环境中,大多数妇女没有常规接受感染检测,尸检也很少进行。
这项前瞻性队列研究将在印度达文盖尔和巴基斯坦卡拉奇的医院进行。在其中一家医院分娩死产或早产儿的所有妇女都有资格入组。在获得同意的情况下,将对参与者及其子女(如适用)进行随访,直至分娩后 28 天。将进行一系列研究测试,以确定感染和可能导致死亡的其他情况。此外,所有常规临床调查都将记录在案。对于死产和在 28 天内死亡的早产儿,如果同意,将进行标准尸检以及微创组织取样。最后,一个专家小组将审查所有可用的死产和新生儿死亡数据,以使用预先指定的指南确定死亡的主要和促成原因。
这将是首批在亚洲资源匮乏的环境中前瞻性获得死产和早产新生儿死亡原因详细信息的研究之一。确定主要死因对于告知最有可能降低南亚高死亡率的策略非常重要。
Clinicaltrials.gov(NCT03438110)印度临床试验注册中心(CTRI/2018/03/012281)。